RT Journal Article
SR Electronic
T1 Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.22.20216028
DO 10.1101/2020.10.22.20216028
A1 Dillon, Laura W.
A1 Ghannam, Jack
A1 Nosiri, Chidera
A1 Gui, Gege
A1 Goswami, Meghali
A1 Calvo, Katherine R.
A1 Lindblad, Katherine E.
A1 Oetjen, Karolyn A.
A1 Wilkerson, Matthew
A1 Soltis, Anthony R.
A1 Sukumar, Gauthaman
A1 Dalgard, Clifton L.
A1 Thompson, Julie
A1 Valdez, Janet
A1 DeStefano, Christin B.
A1 Lai, Catherine
A1 Sciambi, Adam
A1 Durruthy-Durruthy, Robert
A1 Llanso, Aaron
A1 Gulati, Saurabh
A1 Wang, Shu
A1 Ooi, Aik
A1 Dagur, Pradeep K.
A1 McCoy, J. Philip
A1 Burr, Patrick
A1 Li, Yuesheng
A1 Hourigan, Christopher S.
YR 2020
UL http://medrxiv.org/content/early/2020/10/26/2020.10.22.20216028.abstract
AB Genetic mutations associated with acute myeloid leukemia can also be detected in age-related clonal hematopoiesis, making confident assignment of detected variants to malignancy challenging particularly in the post-treatment setting. This has implications for measurable residual disease monitoring, where the relationship between sequencing and flow cytometry is also imperfect. We show, using whole-genome-sequencing informed patient-personalized single-cell DNA and antibody-oligonucleotide sequencing, that it is possible to resolve immunophenotypic identity of clonal architecture.Competing Interest StatementCSH: Research support from Merck and Sellas. AS, RDD, AL, SG, SW, and AO: Employed by and own equity in Mission Bio, Inc. CL: Speakers' Bureau: Astellas, Jazz Pharma; Consulting or Advisory Role: Daiichi, Jazz Pharma, Amgen, Abbvie, Macrogenics, Agios.Funding StatementThis work was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and by the Department of Defense award: HU0001-18-2-0038 to CLD. This work utilized the NHLBI Flow Cytometry Core, the NHLBI Sequencing and Genomics Core and the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected from patients with relapsed or refractory AML after receipt of written informed consent on a National Heart, Lung, and Blood Institute institutional review board-approved protocol in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is available upon request and will be submitted to dbGaP prior to formal publication.